Cheng S L, Lou J, Wright N M, Lai C F, Avioli L V, Riew K D
Division of Bone and Mineral Diseases, Dept. of Internal Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Calcif Tissue Int. 2001 Feb;68(2):87-94.
It has been well established that bone morphogenetic protein-2 (BMP-2) can induce bone formation both in vivo and in vitro, although high concentrations (up to milligrams) of BMP-2 have been required to achieve this effect in vivo. Further, clinical applications are usually limited to a single dose at the time of implantation. In an attempt to prolong the transforming effect of BMP-2 we used a recombinant adenoviral vector carrying the human BMP-2 gene (Adv-BMP2) to transduce marrow-derived mesenchymal stem cells (MSC) of skeletally mature male New Zealand white rabbits. The pluripotential MSC were incubated with Adv-BMP2 overnight followed by culture in growth medium for 1 week. Assays on tissue cultures demonstrated that these Adv-BMP2 transduced MSC produced BMP-2 protein, differentiated into an osteoprogenitor line, and induced bone formation in vitro. These MSC had increased alkaline phosphatase activity, increased expression of type I collagen, osteopontin, and osteocalcin mRNA, and induced matrix mineralization compared with both non-transduced cells and cells transduced with a control adenoviral construct. To analyze the osteogenic potential in vivo, Adv-BMP2-transduced MSC were autologously implanted into the intertransverse process space between L5 and L6 of the donor rabbits. The production of new bone was demonstrated by radiographic examination 4 weeks later in areas implanted with cells transduced with Adv-BMP2, whereas no bone was evident at sites implanted with cells transduced with the control adenoviral construct. Histological examination further confirmed the presence of new bone formation. These accumulated data indicate that it is possible to successfully transduce mesenchymal stem cells with a recombinant adenoviral vector carrying the gene for BMP-2 such that these cells will produce BMP-2, differentiate into an osteoprogenitor line, and induce bone formation both in vitro and in vivo. Moreover, incubation of the Adv-BMP2-transduced cells for an additional 7 days in culture before transplantation enhances the success rate in bone formation (three out of three) as compared with our previous report (one out of five, Calcif Tissue Int 63:357-360, 1998).
骨形态发生蛋白-2(BMP-2)在体内和体外均可诱导骨形成,这一点已得到充分证实,不过在体内要实现这种效果通常需要高浓度(高达毫克级)的BMP-2。此外,临床应用通常仅限于植入时的单次给药。为了延长BMP-2的转化作用,我们使用携带人BMP-2基因的重组腺病毒载体(Adv-BMP2)转导骨骼成熟的雄性新西兰白兔的骨髓间充质干细胞(MSC)。将多能性MSC与Adv-BMP2孵育过夜,然后在生长培养基中培养1周。组织培养分析表明,这些经Adv-BMP2转导的MSC产生BMP-2蛋白,分化为成骨祖细胞系,并在体外诱导骨形成。与未转导细胞和用对照腺病毒构建体转导的细胞相比,这些MSC的碱性磷酸酶活性增加,I型胶原蛋白、骨桥蛋白和骨钙素mRNA的表达增加,并诱导基质矿化。为了分析体内成骨潜力,将经Adv-BMP2转导的MSC自体植入供体兔L5和L6之间的横突间间隙。4周后通过放射学检查证实在植入经Adv-BMP2转导细胞的区域有新骨生成,而在植入用对照腺病毒构建体转导细胞的部位没有明显的骨形成。组织学检查进一步证实了新骨形成的存在。这些累积数据表明,用携带BMP-2基因的重组腺病毒载体成功转导间充质干细胞是可能的,使得这些细胞将产生BMP-2,分化为成骨祖细胞系,并在体外和体内诱导骨形成。此外,与我们之前的报告(五分之一,《钙化组织国际》63:357 - 360, 1998)相比,在移植前将经Adv-BMP2转导的细胞在培养中再孵育7天可提高骨形成的成功率(三分之三)。